Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Novel Nanoparticle Formulations for Retinal Drug Delivery
share announcement

Novel Nanoparticle Formulations for Retinal Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 4214

Special Issue Editor

Dr. José Hurst

E-Mail Website
Guest Editor
University Eye Hospital Tuebingen, Elfriede-Aulhorn - Str. 7, 72076 Tübingen, Germany
Interests: ophthalmology; neurodegeneration; neuroprotection; ex vivo retina cultures; drug delivery; retinal gene therapies; nanoparticle; small molecules therapies

Special Issue Information

Dear Colleagues,

The delivery of drugs intended to reach the retina is very complex. Nanocarriers, such as nanoparticles, can deliver ophthalmic drugs to specific targets and promise to revolutionise the treatment of many eye diseases. To date, the results strongly suggest that ophthalmology stands to benefit enormously from the use of this nanotechnology. In recent decades, nanotechnology appears to be creating new horizons for the treatment of ocular diseases by enabling the controlled release of drugs, ensuring fewer side effects, improving drug bioavailability, and forcing drug uptake into retinal cells. Numerous drug delivery systems have also been investigated regarding their ability to reach the posterior segment of the eye through topical application. The aim of this Special Issue is to provide an update on recent advancements in the synthesis, development and use of nanoparticles for drug delivery and sustained release in the retina, in view of the practical potential of nanoparticles and nanoformulations.

Dr. José Hurst
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nano-based gene/drug delivery to target retinas/retinal explants/organoids 
  • targeted drug delivery to retinal cells 
  • neuroprotection 
  • formulation of nanoparticles for retinas 
  • organic and inorganic nanoparticles 
  • therapies for retinal diseases 
  • depot function of nanoparticles 
  • technologies for targeted delivery of DNA/RNA (ASO/nucleic acid) 
  • active transport/passive transport of nanoparticles

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3718 KiB  
Article
A Multifunctional Hybrid Nanocarrier for Non-Invasive siRNA Delivery to the Retina
by Shogo Nishida, Yuuki Takashima, Ryotaro Udagawa, Hisako Ibaraki, Yasuo Seta and Hiroshi Ishihara
Pharmaceutics 2023, 15(2), 611; https://doi.org/10.3390/pharmaceutics15020611 - 11 Feb 2023
Cited by 4 | Viewed by 1522
Abstract
Drug therapy for retinal diseases (e.g., age-related macular degeneration, the leading cause of blindness) is generally performed by invasive intravitreal injection because of poor drug delivery caused by the blood–retinal barrier (BRB). This study aimed to develop a nanocarrier for the non-invasive delivery [...] Read more.
Drug therapy for retinal diseases (e.g., age-related macular degeneration, the leading cause of blindness) is generally performed by invasive intravitreal injection because of poor drug delivery caused by the blood–retinal barrier (BRB). This study aimed to develop a nanocarrier for the non-invasive delivery of small interfering RNA (siRNA) to the posterior segment of the eye (i.e., the retina) by eyedrops. To this end, we prepared a hybrid nanocarrier based on a multifunctional peptide and liposomes, and the composition was optimized. A cytoplasm-responsive stearylated peptide (STR-CH2R4H2C) was used as the multifunctional peptide because of its superior ability to enhance the complexation, cell permeation, and intracellular dynamics of siRNA. By adding STR-CH2R4H2C to the surface of liposomes, intracellular uptake increased regardless of the liposome surface charge. The STR-CH2R4H2C-modified cationic nanocarrier demonstrated significant siRNA transfection efficiency with no cytotoxicity, enhanced siRNA release from endosomes, and effectively suppressed vascular endothelial growth factor expression in rat retinal pigment epithelium cells. The 2.0 mol% STR-CH2R4H2C-modified cationic nanocarrier enhanced intraocular migration into the retina after instillation into rat eyes. Full article
(This article belongs to the Special Issue Novel Nanoparticle Formulations for Retinal Drug Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

32 pages, 1171 KiB  
Review
Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases
by Binapani Mahaling, Shermaine W. Y. Low, Sanjay Ch, Utkarsh R. Addi, Baseer Ahmad, Thomas B. Connor, Rajiv R. Mohan, Swati Biswas and Shyam S. Chaurasia
Pharmaceutics 2023, 15(7), 2005; https://doi.org/10.3390/pharmaceutics15072005 - 22 Jul 2023
Cited by 1 | Viewed by 2211
Abstract
Retinal diseases are one of the leading causes of blindness globally. The mainstay treatments for these blinding diseases are laser photocoagulation, vitrectomy, and repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) or steroids. Unfortunately, these therapies are associated with ocular complications like [...] Read more.
Retinal diseases are one of the leading causes of blindness globally. The mainstay treatments for these blinding diseases are laser photocoagulation, vitrectomy, and repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) or steroids. Unfortunately, these therapies are associated with ocular complications like inflammation, elevated intraocular pressure, retinal detachment, endophthalmitis, and vitreous hemorrhage. Recent advances in nanomedicine seek to curtail these limitations, overcoming ocular barriers by developing non-invasive or minimally invasive delivery modalities. These modalities include delivering therapeutics to specific cellular targets in the retina, providing sustained delivery of drugs to avoid repeated intravitreal injections, and acting as a scaffold for neural tissue regeneration. These next-generation nanomedicine approaches could potentially revolutionize the treatment landscape of retinal diseases. This review describes the availability and limitations of current treatment strategies and highlights insights into the advancement of future approaches using next-generation nanomedicines to manage retinal diseases. Full article
(This article belongs to the Special Issue Novel Nanoparticle Formulations for Retinal Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop